Published in BMJ on May 01, 2004
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science (2012) 6.79
Prognosis for patients with chronic low back pain: inception cohort study. BMJ (2009) 3.07
Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA (2008) 2.47
Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles. JAMA (2015) 2.17
Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol (2012) 2.15
Leishmania manipulation of sand fly feeding behavior results in enhanced transmission. PLoS Pathog (2007) 1.72
Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. Cell Cycle (2012) 1.65
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer (2013) 1.48
Nicotine administration and withdrawal affect survival in systemic inflammation models. J Appl Physiol (1985) (2008) 1.48
Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. Breast Cancer Res (2016) 1.39
Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol (2009) 1.34
Pyrones as bacterial signaling molecules. Nat Chem Biol (2013) 1.30
Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS One (2012) 1.23
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A (2015) 1.19
Evaluation of lysine biosynthesis as an antifungal drug target: biochemical characterization of Aspergillus fumigatus homocitrate synthase and virulence studies. Eukaryot Cell (2010) 1.14
Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer (2011) 1.11
Characterization of cerebral malaria in the outbred Swiss Webster mouse infected by Plasmodium berghei ANKA. Int J Exp Pathol (2009) 1.10
Does wait-list size at registration influence time to surgery? Analysis of a population-based cardiac surgery registry. Health Serv Res (2006) 1.05
Drosophila melanogaster-based screening for multihost virulence factors of Pseudomonas aeruginosa PA14 and identification of a virulence-attenuating factor, HudA. Infect Immun (2008) 1.04
Gender and age differences in the recurrence of sickness absence due to common mental disorders: a longitudinal study. BMC Public Health (2010) 0.99
Temporal distribution and parasite load kinetics in blood and tissues during Neospora caninum infection in mice. Infect Immun (2006) 0.97
SMARTer discontinuation trial designs for developing an adaptive treatment strategy. J Child Adolesc Psychopharmacol (2012) 0.96
Dialkylresorcinols as bacterial signaling molecules. Proc Natl Acad Sci U S A (2014) 0.95
A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. Hum Mol Genet (2011) 0.94
A 41-gene signature derived from breast cancer stem cells as a predictor of survival. J Exp Clin Cancer Res (2014) 0.93
GABAergic synaptic plasticity during a developmentally regulated sleep-like state in C. elegans. J Neurosci (2011) 0.92
Experience of surgical morbidity after palliative surgery in patients with gastric carcinoma. Gastric Cancer (2007) 0.91
Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol (2010) 0.91
Reduced medium-term mortality following primary total hip and knee arthroplasty with an enhanced recovery program. A study of 4,500 consecutive procedures. Acta Orthop (2013) 0.88
Influence of Neospora caninum intra-specific variability in the outcome of infection in a pregnant BALB/c mouse model. Vet Res (2010) 0.87
Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res (2011) 0.87
Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody. J Gastroenterol (2012) 0.87
Using the Statecharts paradigm for simulation of patient flow in surgical care. Health Care Manag Sci (2008) 0.87
Physical exercise-induced changes in the core body temperature of mice depend more on ambient temperature than on exercise protocol or intensity. Int J Biometeorol (2013) 0.85
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs (2010) 0.85
Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol (2010) 0.84
Embryonic senescence and laminopathies in a progeroid zebrafish model. PLoS One (2011) 0.84
Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. Transfusion (2014) 0.83
Wolbachia-Host Interactions: Host Mating Patterns Affect Wolbachia Density Dynamics. PLoS One (2013) 0.82
Radiation therapy for primary vaginal carcinoma. J Radiat Res (2013) 0.82
In Vitro and In Vivo Anticancer Effects of Sterol Fraction from Red Algae Porphyra dentata. Evid Based Complement Alternat Med (2013) 0.81
Physical exercise performance in temperate and warm environments is decreased by an impaired arterial baroreflex. PLoS One (2013) 0.81
Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer (2015) 0.80
Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol (2016) 0.80
A genome-wide systematic analysis reveals different and predictive proliferation expression signatures of cancerous vs. non-cancerous cells. PLoS Genet (2013) 0.80
Direct measurement of microtubule attachment strength to yeast centrosomes. Mol Biol Cell (2017) 0.79
AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects. Autophagy (2016) 0.78
5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression. Oncotarget (2016) 0.78
A clinical trial comparing parenteral oxytetracyline and enrofloxacin on time to recovery in sheep lame with acute or chronic footrot in Kashmir, India. BMC Vet Res (2012) 0.78
Winners and losers: tropical forest tree seedling survival across a West African forest-savanna transition. Ecol Evol (2016) 0.77
Evaluation of the protection conferred by a naturally attenuated Neospora caninum isolate against congenital and cerebral neosporosis in mice. Vet Res (2012) 0.77
Cumulative incidence for wait-list death in relation to length of queue for coronary-artery bypass grafting: a cohort study. J Cardiothorac Surg (2006) 0.77
Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatr Nephrol (2016) 0.77
Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. BMC Genomics (2010) 0.76
Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival. Proc Natl Acad Sci U S A (2015) 0.76
Cell-to-cell distances between tumor-infiltrating inflammatory cells have the potential to distinguish functionally active from suppressed inflammatory cells. Oncoimmunology (2016) 0.76
Influence of durable mechanical circulatory support and allosensitization on mortality after heart transplantation. J Heart Lung Transplant (2016) 0.75
Dual promoters of the major catalase (KatA) govern distinct survival strategies of Pseudomonas aeruginosa. Sci Rep (2016) 0.75
Elements of statistical treatment of speech and hearing science data. Stammering Res (2005) 0.75
Oxalate induces breast cancer. BMC Cancer (2015) 0.75
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol (2017) 0.75
An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy. Br J Cancer (2016) 0.75
Assessment of pathologic response in patients with locally advanced rectal cancer: implications of the park et Al. Study. J Adv Pract Oncol (2013) 0.75
Hierarchical organization of a Sardinian sand dune plant community. PeerJ (2016) 0.75
Finding the Balance: Fertility Control for the Management of Fragmented Populations of a Threatened Rock-Wallaby Species. Animals (Basel) (2015) 0.75
Survival analysis, more than meets the eye. Biochem Med (Zagreb) (2017) 0.75
Effectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol (2016) 0.75
Big genomics and clinical data analytics strategies for precision cancer prognosis. Sci Rep (2016) 0.75
Costly learning: preference for familiar food persists despite negative impact on survival. Biol Lett (2016) 0.75
The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: a population-based observational study. J Cardiothorac Surg (2013) 0.75
Nf-GH, a glycosidase secreted by Naegleria fowleri, causes mucin degradation: an in vitro and in vivo study. Future Microbiol (2017) 0.75
A Practical Guide to Visualization and Statistical Analysis of R. solanacearum Infection Data Using R. Front Plant Sci (2017) 0.75
Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight (2017) 0.75
Morpho-functional changes of fat body in bacteria fed Drosophila melanogaster strains. J Mol Histol (2011) 0.75
Surgical approach for recurrent inguinal hernias: a Nationwide Cohort Study. Hernia (2016) 0.75
Time to event (survival) data. BMJ (1998) 4.29
Survival probabilities (the Kaplan-Meier method). BMJ (1998) 3.98
Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery (1994) 1.85
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA (2004) 23.87
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 22.34
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol (2009) 17.92
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
CONSORT statement: extension to cluster randomised trials. BMJ (2004) 16.50
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med (2010) 16.11
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med (2008) 13.87
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (2010) 12.98
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
Epidemiology and reporting characteristics of systematic reviews. PLoS Med (2007) 11.51
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust (2006) 11.40
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ (2004) 10.75
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ (2008) 9.98
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med (2010) 9.30
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med (2006) 8.25
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Comparison of registered and published primary outcomes in randomized controlled trials. JAMA (2009) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One (2009) 7.60
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (2014) 7.55
Consort 2010 statement: extension to cluster randomised trials. BMJ (2012) 7.47
Guidance for developers of health research reporting guidelines. PLoS Med (2010) 7.43
Diagnostic tests 4: likelihood ratios. BMJ (2004) 7.33
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med (2010) 6.88
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (2003) 6.61
Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet (2002) 6.61
Epidemiology and reporting of randomised trials published in PubMed journals. Lancet (2005) 6.55
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol (2013) 5.93
CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med (2008) 5.85
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (2010) 5.70
The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ (2010) 5.58
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat (2007) 5.52
An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ (2009) 5.45
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ (2005) 5.36
The design of simulation studies in medical statistics. Stat Med (2006) 5.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Ghost authorship in industry-initiated randomised trials. PLoS Med (2007) 4.95
Quantification of the completeness of follow-up. Lancet (2002) 4.77
Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA (2012) 4.73
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA (2010) 4.56
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Prognosis and prognostic research: what, why, and how? BMJ (2009) 4.46
An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ (2010) 4.46
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med (2009) 4.43
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ (2009) 4.38
Prognosis and prognostic research: Developing a prognostic model. BMJ (2009) 4.38
Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev (2012) 4.36
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med (2015) 4.32
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2002) 4.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials (2010) 4.28
CONSORT for reporting randomised trials in journal and conference abstracts. Lancet (2008) 4.20
Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials (2008) 4.17
Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J (2002) 3.96
CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 3.96
Developing a prognostic model in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol (2003) 3.90
CONSORT 2010 changes and testing blindness in RCTs. Lancet (2010) 3.68
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med (2010) 3.63
Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med (2008) 3.63
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Ten steps towards improving prognosis research. BMJ (2009) 3.44
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38
Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev (2012) 3.37
Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med (2008) 3.31
Taking healthcare interventions from trial to practice. BMJ (2010) 3.27